Armata Pharmaceuticals (ARMP)
(Delayed Data from AMEX)
$2.56 USD
+0.02 (0.59%)
Updated Aug 8, 2024 10:00 AM ET
After-Market: $2.61 +0.05 (1.95%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ARMP 2.56 +0.02(0.59%)
Will ARMP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARMP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARMP
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
ARMP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why
Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
Other News for ARMP
Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
Armata Pharmaceuticals receives $5.25M of funding from DoD
Armata Pharmaceuticals Updates Chief Medical Officer’s Compensation
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024